BIRC5 (survivin) showed different effects with herbicide exposure at the concentration of 100 [micro]M.
The PCR primers used in this study 5'-CCCAGCCAAAGAAGAAACCA-3'- (fwd) P53 5'-TTCCAAGGCCTCATTCAGCT-3' (rv) 5 '-AGAACTGGCCCTTCTTGGAGG-3 '-(fwd) BIRC5 5'-CTTTTTATGTTCCTCTATGGGGTC-3' (rv) 5'-TGCTTCAGGGTTTCATCCAG-3' (fwd) BAX 5'-GGCGGCAATCATCCTCTG-3' (rv) 5'-AGGAAGTGAACATTTCGGTGAC-3' (fwd) BCL-2 5'-GCTCAGTTCCAGGACCAGGC-3' (rv) 5'-ACATGGCGTGTCATAAAATACC-3' (fwd) CAS3 5'-CACAAAGCGACTGGATGAAC-3' (rv) 5'-CCAGAGATTCGCAAACCAGAGG-3' (fwd) CAS9 5'-GAGCACCGACATCACCAAATCC-3' (rv) Housekeeping PPIA 5'-AAGGGTTCCTGCTTTCAC-3' (fwd) 5'-GGACCCGTATGCTTTAGG-3' (rv) Table 2.
Of these 15 hub genes, PHLPP2, DLG4, and MYC displayed significant positive correlation with overall survival while TP53, TOP2A, CDK1, CCNB1, CDC20, CCNA2, NDC80, AURKA, BIRC5, CCNB2, KIF11, and MAD2L1 negatively correlated with overall survival in patients with glioma.
Caption: Figure 3: Prognostic value of 15 genes (TP53, TOP2A, CDK1, PHLPP2, DLG4, CCNB1, MYC, CDC20, CCNA2, NDC80, AURKA, BIRC5, CCNB2, KIF11, and MAD2L1) in glioma patients.
have shown inhibition of the STAT3 pathway with downregulation of BCL2L1, BIRC5, and MCL1 after incubation with CDDO-Me .
Afterwards, cells were lysed and whole proteins lysates were analysed by Western blot for altered expression of X-linked inhibitor of apoptosis protein (XIAP), baculoviral IAP repeat containing 5 (BIRC5), myeloid cell leukemia 1 (MCL1), B-cell lymphoma 2 (BCL2), and BCL2 like 1 (BCL2L1).
BIRC5 has been reported to participate in modulation of diverse cellular processes such as proliferation, adhesion, apoptosis, migration and invasion during growth, development, repair, maintenance, and regression of a wide variety of mesenchymal tissues [25-28].
The qRT-PCR confirmation results of six lncRNAs (RP11517C16.2-001, FR271872, LOC283352, RP11-401E9.3, FGFR3P, and XXbac-BPG16N22.5) and mRNAs (NOS2, C13orf15, FOS, FCN2, SPINT1, PLAC8, BIRC5, and COL19A1) were consistent with the microarray data which confirmed the reliability of our microarray analysis.
The detection rates (Cq <40) for each gene ranging from 21% (BIRC5) to 100% (ESR1 and VEGFA)in normal breast tissue and from 81% (BIRC5) to 100% (ERBB2 and VEGFA) in tumor tissue sections are summarized in Fig.
The finding of an increased expression level in tumors relative to adjacent normal tissues for the majority of targets is in line with their potential function as mitogens (ESR1, PGR, and ERBB2) or dysregulated oncogenes (BIRC5, VEGFA, and TOP2A) in breast cancer.
In agreement, both populations with increased receptor expression, pro-Bs and immatures, upregulate the expression of survival factor BIRC5
in response to PRL.
Immunohistochemical labeling of several genes including CDKN1A, (12) PSCA, (7,13) MMP7, (14) MUC4, (15,16) CLDN18, (17) ANXA2, (18) BIRC5
, (19,20) MUC5, (7) and S100P (21) in multiple PanIN lesions has shown a progressive increase in their expression from low- to high-grade PanINs and leading into invasive cancer.